Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:54:05.236Z.
Consensus retrieved: 2026-10-06T16:48:06.732Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:54:05.236Z.
Quote observation: 2026-10-06T19:50:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 63abd2f0ca123cd70ec90b05524e088c06a7031a31b9a0ff7cc8ba3286916f5d
Forward PE Ratio (N/A) = Dated Quote Price ($14.48) / Consensus Forward EPS ($-8.03)
FORWARD PE RATIO
N/A
Sutro Biopharma, Inc.
Market Cap
$140.16M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Sutro Biopharma, Inc. (STRO) | $140.16M | N/A |
| Alpha Cognition Inc (ACOG)vs › | $139.78M | N/A |
| Immuneering Corporation (IMRX)vs › | $139.04M | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $138.03M | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.10M | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $144.06M | 7.18 |
| Organigram Global Inc. (OGI)vs › | $136.58M | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.51M | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $144.73M | N/A |
| Atrium Therapeutics, Inc. (RNA)vs › | $135.73M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $14.48, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-8.03 | $-9.85 – $-6.10 | 7 | n/m |
| 2027-12-31 | $-6.39 | $-9.55 – $-3.96 | 8 | n/m |
| 2028-12-31 | $-6.19 | $-9.52 – $-2.36 | 9 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
